NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
43 hedge funds and large institutions have $13.4M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
42% less capital invested
Capital invested by funds: $23.3M → $13.4M (-$9.88M)
Holders
43
Holding in Top 10
1
Calls
$14K
Puts
–
Top Buyers
| 1 | +$536K | |
| 2 | +$47.3K | |
| 3 | +$46.3K | |
| 4 |
Charles Schwab
San Francisco,
California
|
+$32K |
| 5 |
Renaissance Technologies
New York
|
+$25.5K |
Top Sellers
| 1 | -$164K | |
| 2 | -$70K | |
| 3 | -$69.4K | |
| 4 |
Two Sigma Advisers
New York
|
-$48K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$34K |